| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $57.9M | +59.6% |
| R&D Expense | $466.3M | +7.2% |
| SG&A Expense | $125.8M | +8.0% |
| Operating Income | -$534.3M | -3.7% |
| Net Income | -$519.0M | -7.9% |
| EPS (Basic) | -$5.25 | +3.1% |
| EPS (Diluted) | -$5.25 | +3.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $189.2M | -16.6% |
| Short-term Investments | $412.3M | -39.8% |
| Accounts Receivable | $8.5M | -76.6% |
| Current Assets | $639.9M | -35.9% |
| Total Assets | $1.19B | -8.5% |
| Current Liabilities | $110.9M | -3.8% |
| Total Liabilities | $319.1M | +27.2% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$348.9M | +11.5% |
| Capital Expenditures | $5.8M | -58.7% |
| Investing Cash Flow | $125.6M | +500.6% |
| Financing Cash Flow | $185.7M | +42.5% |
| Free Cash Flow | -$354.7M | +13.1% |
| Stockholders' Equity |
| $872.0M |
| -17.0% |